Penicillin One Dose Effective Against Syphilis
- A late-stage clinical trial suggests a one-time injection of benzathine penicillin G (BPG) is as effective as the current standard three-dose regimen for early-stage syphilis,possibly easing strain on...
- Syphilis is a sexually transmitted bacterial infection caused by Treponema pallidum.
- Untreated syphilis can led to serious health problems, including damage to the heart, brain, and other organs.
“`html
Single-Dose Syphilis Treatment Shows Promise Amid Ongoing Drug Shortages
Table of Contents
A late-stage clinical trial suggests a one-time injection of benzathine penicillin G (BPG) is as effective as the current standard three-dose regimen for early-stage syphilis,possibly easing strain on limited supplies.
What is Syphilis and Why is Treatment Challenging?
Syphilis is a sexually transmitted bacterial infection caused by Treponema pallidum. It’s spread through direct contact with a syphilitic sore, known as a chancre, typically during vaginal, anal, or oral sex. The Centers for Disease Control and Prevention (CDC) reports a notable increase in syphilis cases in recent years, with a notably alarming rise in congenital syphilis-syphilis passed from a pregnant person to their baby according to CDC data released in October 2023.
Untreated syphilis can led to serious health problems, including damage to the heart, brain, and other organs. Treatment with antibiotics, specifically penicillin, is highly effective, but access to the standard treatment, benzathine penicillin G (BPG), has been repeatedly disrupted by drug shortages.
The BPG Shortage: A Recurring Crisis
Benzathine penicillin G, marketed as Bicillin L-A, is the recommended treatment for early-stage syphilis. Though,the United States has experienced numerous shortages of BPG over the past two decades,including a particularly prolonged shortage lasting nearly five years. The Food and Drug Administration (FDA) maintains a list of current and resolved drug shortages, highlighting the ongoing vulnerability of the pharmaceutical supply chain.
Most recently, in July 2025, Pfizer recalled several lots of Bicillin L-A due to potential particulate contamination, exacerbating an existing shortage that began two years prior. To address the shortfall,the U.S. is currently importing the medication from other countries, a temporary solution with logistical and cost implications. Pfizer announced the recall on July 18, 2025.
| Year | Event |
|---|---|
| 2005-2010 | Prolonged BPG shortage |
| 2023 | BPG shortage begins |
| July 2025 | Pfizer recalls Bicillin L-A lots due to contamination |
New Research: A Potential One-Dose Solution
A recent late-stage clinical trial has demonstrated that a single injection of BPG is as effective as the standard three-injection regimen in treating early-stage syphilis. While the specific details of the trial are still being published, preliminary findings suggest this could be a game-changer for public health officials grappling with the ongoing drug shortages. The study’s results offer the possibility of stretching the limited BPG supply further, ensuring more patients receive timely treatment.
researchers emphasize that further examination is needed to confirm these findings and assess the